JP2022518441A5 - - Google Patents

Info

Publication number
JP2022518441A5
JP2022518441A5 JP2021541095A JP2021541095A JP2022518441A5 JP 2022518441 A5 JP2022518441 A5 JP 2022518441A5 JP 2021541095 A JP2021541095 A JP 2021541095A JP 2021541095 A JP2021541095 A JP 2021541095A JP 2022518441 A5 JP2022518441 A5 JP 2022518441A5
Authority
JP
Japan
Prior art keywords
seq
formulation according
formulation
heavy chain
cdr2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021541095A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022518441A (ja
JP7539897B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/013916 external-priority patent/WO2020150496A1/en
Publication of JP2022518441A publication Critical patent/JP2022518441A/ja
Publication of JP2022518441A5 publication Critical patent/JP2022518441A5/ja
Application granted granted Critical
Publication of JP7539897B2 publication Critical patent/JP7539897B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021541095A 2019-01-16 2020-01-16 ヒトcd137に結合する抗体の製剤およびその使用 Active JP7539897B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962793342P 2019-01-16 2019-01-16
US62/793,342 2019-01-16
US202062960501P 2020-01-13 2020-01-13
US62/960,501 2020-01-13
PCT/US2020/013916 WO2020150496A1 (en) 2019-01-16 2020-01-16 Formulations of antibodies that bind human cd137 and uses thereof

Publications (3)

Publication Number Publication Date
JP2022518441A JP2022518441A (ja) 2022-03-15
JP2022518441A5 true JP2022518441A5 (OSRAM) 2023-01-20
JP7539897B2 JP7539897B2 (ja) 2024-08-26

Family

ID=69724049

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021541095A Active JP7539897B2 (ja) 2019-01-16 2020-01-16 ヒトcd137に結合する抗体の製剤およびその使用

Country Status (12)

Country Link
US (1) US20220111047A1 (OSRAM)
EP (1) EP3911679A1 (OSRAM)
JP (1) JP7539897B2 (OSRAM)
KR (1) KR20210131312A (OSRAM)
CN (1) CN113474371B (OSRAM)
AU (1) AU2020208397A1 (OSRAM)
BR (1) BR112021013571A2 (OSRAM)
CA (1) CA3127072A1 (OSRAM)
IL (1) IL284208A (OSRAM)
MX (1) MX2021008453A (OSRAM)
SG (1) SG11202107538VA (OSRAM)
WO (1) WO2020150496A1 (OSRAM)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024508746A (ja) * 2021-02-17 2024-02-28 アプティーボ リサーチ アンド デベロップメント エルエルシー 4-1bbおよびox40結合タンパク質を含む組成物および使用方法
CN118090983B (zh) * 2024-04-26 2024-09-06 山东齐都药业有限公司 布比卡因/美洛昔康复方凝胶中活性物质的检测方法

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4863457A (en) 1986-11-24 1989-09-05 Lee David A Drug delivery device
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
EP0768377A1 (en) 1988-09-02 1997-04-16 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
KR0185215B1 (ko) 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
AU662148B2 (en) 1991-04-10 1995-08-24 Scripps Research Institute, The Heterodimeric receptor libraries using phagemids
NL9101953A (nl) 1991-11-21 1993-06-16 Seed Capital Investments Testinrichting omvattende een plaat met een veelvoud van putjes met een bijbehorende doseerinrichting, alsmede een kit die deze inrichtingen omvat en toepassing van de inrichtingen.
PT1696031E (pt) 1991-12-02 2010-06-25 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
PT1621554E (pt) 1992-08-21 2009-07-13 Univ Bruxelles Imunoglobtainas desprovidas de cadeias leves
US6838254B1 (en) 1993-04-29 2005-01-04 Conopco, Inc. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
JPH08511420A (ja) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド 抗 体
JPH09506262A (ja) 1993-12-08 1997-06-24 ジェンザイム・コーポレイション 特異的抗体の製造方法
PT744958E (pt) 1994-01-31 2003-11-28 Univ Boston Bancos de anticorpos policlonais
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
ATE219517T1 (de) 1995-08-18 2002-07-15 Morphosys Ag Protein-/(poly)peptidbibliotheken
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
WO1997042217A1 (en) 1996-05-06 1997-11-13 The Uab Research Foundation Radiolabeled fusion toxins for cancer therapy
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
IL138608A0 (en) 1998-04-02 2001-10-31 Genentech Inc Antibody variants and fragments thereof
US6995259B1 (en) 1998-10-23 2006-02-07 Sirna Therapeutics, Inc. Method for the chemical synthesis of oligonucleotides
EP1197755A1 (en) 2000-10-11 2002-04-17 Pepscan Systems B.V. Identification of protein binding sites
US8685435B2 (en) 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
JP5364870B2 (ja) 2005-08-19 2013-12-11 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP3124497B1 (en) 2007-09-14 2020-04-15 Adimab, LLC Rationally designed, synthetic antibody libraries and uses therefor
EP2453874A2 (en) * 2009-07-14 2012-05-23 Biogen Idec MA Inc. Methods for inhibiting yellow color and peroxide formation in a composition
CA2781311C (en) * 2009-12-07 2019-03-12 The Board Of Trustees Of The Leland Stanford Junior University Methods for enhancing anti-tumor antibody therapy
KR102024922B1 (ko) 2010-07-16 2019-09-25 아디맵 엘엘씨 항체 라이브러리
SG10201912092VA (en) 2010-09-09 2020-02-27 Pfizer 4-1bb binding molecules
CA2931641C (en) 2013-12-30 2022-05-10 Epimab Biotherapeutics Inc. Fabs-in-tandem immunoglobulin and uses thereof
MY188749A (en) * 2015-04-17 2021-12-28 Bristol Myers Squibb Co Compositions comprising a combination of nivolumab and ipilimumab
CN113214398B (zh) * 2015-09-22 2022-04-08 苏州丁孚靶点生物技术有限公司 抗人cd137的完全人抗体及其应用
EP3652209A2 (en) * 2017-07-11 2020-05-20 Compass Therapeutics LLC Agonist antibodies that bind human cd137 and uses thereof
US11718679B2 (en) * 2017-10-31 2023-08-08 Compass Therapeutics Llc CD137 antibodies and PD-1 antagonists and uses thereof

Similar Documents

Publication Publication Date Title
US20260115254A1 (en) Immune-cell targeted bispecific chimeric proteins and uses thereof
CN109912683B (zh) 一种细胞毒素分子、偶联物及其制备方法和应用
US11873281B2 (en) Conjugates of cell binding molecules with cytotoxic agents
US20260091081A1 (en) A formulation of a conjugate of a tubulysin analog to a cell-binding molecule
TWI440470B (zh) 含改良抗體分子之醫藥配方
US7939074B2 (en) Combination of an anti-EP-CAM antibody with a chemotherapeutic agent
RU2633509C2 (ru) Стабильные составы антител против рецептора программируемой смерти pd-1 человека и относящиеся к ним способы лечения
JP2021517129A5 (OSRAM)
JP2022036932A5 (OSRAM)
IL275274B1 (en) Conjugation of a tubulin analog with branched linkers
JP2001518930A (ja) 抗cd−22抗体を使用したb細胞悪性疾患の免疫療法
CN111050791A (zh) 用于抗tim-3抗体的给药方案及其用途
JP2013500947A5 (OSRAM)
CN107252485A (zh) 用于诱导对疾病的免疫应答的组合疗法
JP2022507606A (ja) Il-7タンパク質と免疫チェックポイント阻害剤の組み合わせで腫瘍を治療する方法
KR20210039395A (ko) 마스킹된 항체의 약제학적 제형
AR129062A1 (es) Composiciones farmacéuticas de proteínas terapéuticas y métodos de uso
CN119424632A (zh) 治疗结直肠癌的联用药物组合物
JP2025504419A5 (OSRAM)
TW202034925A (zh) Cdk4/6抑制劑聯合免疫治療在製備治療淋巴瘤的藥物中的用途
TW202120550A (zh) 雙特異性蛋白質
CN111683681A (zh) 包含抗ox40抗体的制剂、其制备方法及其用途
EP4090430A1 (en) Method of treating a tumor with a combination of il-7 protein and a bispecific antibody
JP2024505128A5 (OSRAM)
TH2101004101A (th) สูตรผสมของแอนติบอดีที่จับ cd137 ของมนุษย์และการใช้สูตรผสมนั้น